12,585 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by Entropy Technologies LP

Entropy Technologies LP bought a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 12,585 shares of the medical equipment provider’s stock, valued at approximately $1,025,000.

Several other institutional investors have also recently modified their holdings of HOLX. Price T Rowe Associates Inc. MD raised its holdings in shares of Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after acquiring an additional 2,753,016 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Hologic by 21.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after purchasing an additional 450,190 shares during the last quarter. Black Creek Investment Management Inc. grew its holdings in shares of Hologic by 60.9% during the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after buying an additional 885,524 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Hologic by 5.7% in the second quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after buying an additional 124,739 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Hologic by 4.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after buying an additional 87,176 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HOLX has been the subject of a number of recent analyst reports. Raymond James lifted their price objective on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. UBS Group raised their price objective on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Stephens reaffirmed an “overweight” rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, October 15th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Trading Down 0.7 %

NASDAQ:HOLX opened at $79.18 on Thursday. The company has a market cap of $18.39 billion, a PE ratio of 23.78, a P/E/G ratio of 2.52 and a beta of 0.98. The business’s 50 day moving average is $80.84 and its two-hundred day moving average is $78.22. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 52 week low of $67.59 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the previous year, the firm earned $0.89 earnings per share. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.